Síndrome de intestino irritable (SII): Nuevos conceptos en 2023.

Autores/as

  • William Otero R. Universidad Nacional de Colombia
  • Lina Otero P. Centro de Gastroenterología y Endoscopia
  • Hernando Marulanda F. Hospital Universitario Nacional de Colombia

DOI:

https://doi.org/10.56050/01205498.2182

Palabras clave:

síndrome, intestino irritable, eje intestino cerebro, dolor abdominal, distensión abdominal, deposiciones

Resumen

El síndrome de intestino irritable, considerado antes como un trastorno funcional, forma actualmente parte del grupo de los trastornos de la interacción del eje intestino-cerebro, una enfermedad orgánica que se identifica clínicamente por la presencia de dolor abdominal recurrente y alteración en la frecuencia o consistencia de las heces. Es una patología multifactorial con impacto negativo en la calidad de vida y hasta el momento, incurable. El objetivo del tratamiento es controlar los síntomas, lo que representa un alto costo para los servicios de salud a nivel mundial. El presente artículo revisa la epidemiología, fisiopatología, el tratamiento y algunos posibles factores relacionados como las alteraciones en la motilidad gastrointestinal, hipersensibilidad visceral, inflamación intestinal, alteración de la microbiota intestinal o disbiosis, sobrecrecimiento bacteriano y la respuesta inmunológica a la dieta.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

William Otero R., Universidad Nacional de Colombia

FAGA, FASGE, FACP. Profesor Titular de Medicina, Unidad de Gastroenterología, Universidad Nacional de Colombia, Hospital Universitario Nacional de Colombia. Expresidente de la Asociación Colombiana de Gastroenterología, de la Asociación Colombiana de Endoscopia Digestiva, de la Asociación Colombiana de Medicina Interna, Capítulo Central. Gastroenterólogo, Centro de gastroenterología y Endoscopia, Bogotá, Colombia.

Lina Otero P., Centro de Gastroenterología y Endoscopia

Gastroenteróloga, Centro de Gastroenterología y Endoscopia, Gastroenteróloga.

Hernando Marulanda F., Hospital Universitario Nacional de Colombia

Docente de Gastroenterología, Hospital Universitario Nacional de Colombia. Gastroenterólogo Centro de Gastroenterología y Endoscopia, Bogotá, Colombia.

Referencias bibliográficas

Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology. 2016;150(6):1262-1279.

Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675- 1688.

Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44.

Buono, J, Carson R, Flores N. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.

Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20(7):455-62

Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada and United Kingdom. Gastroenterology. 2020; 158(5):1262-73.

Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.

Lacy BE, Mearin F, Chang L, Chey W, Lembo A, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-1491.

Camilleri M. Irritable Bowel Syndrome: Straightening the road from the Rome criteria. Neurogastroenterol Motil. 2020;32(11):e13957.

Lacy BE, Cangemi DJ. A Pragmatic Approach to the Evaluation and Treatment of Abdominal Bloating. Am J Gastroenterol. 2022;117(5):701-705.

Camilleri M1. Sex as a biological variable in irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(7): e13802.

Hearn M, Whorwell PJ, Vasant DH. Stigma and irritable bowel syndrome: ¿a taboo subject? Lancet Gastroenterol Hepatol. 2020;5(6):607-615.

Ghoshal UC. Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros. J Neurogastroenterol Motil. 2017;23(3):334-340.

O´toole PW, Shnahan F. Transplanting microbes for irritable bowels or irritade microbes or both?. Gastroenterology. 2021;160(1):15-16.

Agrawal A, Houghton LA, Reilly B, Morris J, Whorwell PJ. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol. 2009;104 (8):1998-2004.

Simrén M, Castedal M, Svedlund J, Abrahamsson H, Björnsson E. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci. 2000; 45:2151.

Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol. 2006;41(3):217.

Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19(1 Suppl):62e88.

Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.

Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96(5):1499-506.

Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology. 2002;122(7):1748-55.

Ghoshal UC. Marshall and Warren Lecture 2019: A paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment. J Gastroenterol Hepatol. 2020;35(5):712-721.

Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, Spiller RC. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19(1 Suppl):62-88.

Iovino P, Tremolaterra F, Consalvo D, Sabbatini F, Mazzacca G, Ciacci C. Perception of electrocutaneous stimuli in irritable bowel syndrome. Am J Gastroenterol. 2006;101(3):596-603.

Wilder-Smith CH, Robert-Yap J. Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome. World J Gastroenterol. 2007;13827):3699-704.

Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology. 1997;112(1):64-72.

Song GH, Venkatraman V, Ho KY, Chee MW, Yeon KG, Wilder-Smith CH. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain. 2006;126(1-3):79.

Cenac N, Bautzova T, Le Faouder P, Veldhuis NA, Poole DP, Rolland C, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology. 2015;149(2):433-44.

Bueno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol. 2000;278(5):G670-6.

Faure C, Patey N, Gauthier C, et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010;139(1):249-58.

Ruffle JK, Tinkler L, Emmett C, Ford AC, Nachev P, Aziz Q, Farmer AD, Yiannakou Y. Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach. Am J Gastroenterol. 2021;116(1):142-151.

Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913-21.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693-700.

Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci. 2008;12 Suppl 1:95-102.

Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: ¿plasma cytokines as a potential biomarker? Gastroenterology. 2006;130(2):304-10.

Gecse K, Róka R, Ferrier L, Leveque M, Eutamen H, Cartier C, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57(5):591-99.

Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203-9.

Choghakhori R, Abbasnezhad A, Hasanvand A, Amani R. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine 2017;93:34- 43.

Chao G, Wang Z, Chen X, et al. Cytokines in the colon, central nervous

system and serum of irritable bowel syndrome rats. Eur J Med Res. 2021; 26(1):7-14.

Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immuno- modulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-118.

Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313-323.

Pimentel M, Lembo A. Microbiome and Its Role in Irritable Bowel Syndrome. Dig Dis Sci. 2020;65(3):829-839.

Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157(1):97-108.

Bhattarai Y, Muniz D, Kashyap P. Irritable bowel syndrome: a gut microbiota-related disorder?. Am J Physiol Gastrointest Liver Physiol. 2017;312(1):G52-G62.

Jeffery I, O’Toole P, Öhman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006.

Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100(2):373- 382.

Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-78.

Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11- 12):1157-60.

Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-419.

Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56(6):1612-1618.

Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry. 2020;11:664.

Pimentel M, Lin HC, Enayati P, van der Burg B, Lee HR, Chen JH, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1089-G1095.

Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802-10.

Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56(6):1612-1618.

Kim G, Deepinder F, Morales W, Hwang L, Weitsman S, Chang C, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipationpredominant IBS and methane on breath. Dig Dis Sci. 2012;57(12):3213-8.

Otero L, Otero L. Otero L, Otero W. Síndrome De Intestino Irritable; Cómo se trata en 2022. En: Marulanda H (Edit) Temas Escogidos de Gastroenterología. Asociación Colombiana de Gastroenterología, Alma Digital SAS, Bogotá; 2021, pág: 208-54.

Weitsman S, Celly S, Leite G, Mathur R, Sedighi R, Barlow GM, et al. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. Dig Dis Sci. 2022;67(1):224-232.

Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences. Eur J Clin Nutr. 2006;60(5):667-672.

Moayyedi P, Simrén M, Bercik P. Evidence- based and mechanistic insights into exclusion diets for IBS. Nat Rev Gastroenterol Hepatol. 2020;17(7):406-413.

Thomas A, Quigley EMM. Diet and irritable bowel syndrome. Curr Opin Gastroenterol. 2015;31(2):166-171.

Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40(7):800-8.

Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004;53(10):1459-67.

Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the “no man’s land” of gluten sensitivity. Am J Gastroenterol. 2009;104(6):1587-94.

Vazquez-Roque MI, Camilleri M, Smyrk T,Murray JA, Marietta E, O’Neill J et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903 -911.

Thomas A, Quigley EMM. Diet and irritable bowel syndrome. Curr Opin Gastroenterol. 2015;31(2):166-171.

Liu J, Chey WD, Haller E, Eswaran S. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Know and What We Have Yet to Learn. Ann Rev Med 2020;71:303-314.

Appleby RN, Walters JR. The role of bile acids in functional GI disorders. Neurogastroenterol Motil. 2014; 26:1057-1069.

Valentin N, Camilleri M, Altayar O, Vijay- vargiya P, Acosta A, Nelson AD, et al. Bio- markers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut. 2016;65(12):1951-9.

Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3-11.

Oddsson E, Rask-Madsen J, Krag E A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol. 1978;13(4):408-16.

Gottesman-Katz L, Latorre L, Vanner S, et al. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system. Gut. 2021 May;70(5):970-981.

Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3-11.

Martin CR, Osadchiy V, Kalani A, Mayer EA. The braingut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018; 6:133-148

Tarkan K, Ceren O, Esra K, et al. Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders. Nutrients. 2021;13(2):389.

Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology. 2014;146:1500-1512.

Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gutbrain axis. Gut Microbes. 2016;7:365-383.

Mari A, Abu Baker F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020;9(3):E685.

Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):28-35.

Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132-143.

Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. 2011;140:761-8.

Koloski NA, Talley NJ, Boyce PM. A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion. 2005;72(2-3):86-96.

Drossman DA, Leserman J, Nachman G, Li ZM, Gluck H, Toomey TC, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 1990;113(11):828-33.

Talley NJ, Boyce PM, Jones M. Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study. Gut 1998; 42:47.

Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med. 2003;26(4):361-372.

Koloski NA, Jones M, Talley NJ. Evidence that independent gut- to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther. 2016;44(6):592-600.

Jacobs JP, Mayer EA. Psychobiotics: Shaping the Mind with Gut Bacteria. Am J Gastroenterol. 2019;114(7):1034- 1035.

Dlugosz A, Nowak P, D’Amato M, Kermani GM, Nyström J, Abdurahman S, et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015;27(12):1747-1754.

Xu F, Wu C, Guo F, Cui G, Zeng X, Yang B, et al. Transcriptomic analysis of Campylobacter jejuni NCTC 11168. Front Microbiol. 2015;6:452.

Pigrau M, Rodiño-Janeiro BK, Casado-Bedmar M, Lobo B, Vicario M, Santos J, et al. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. Neurogastroenterol Motil. 2016;28(4):463-486.

Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133-146. 93. Pigrau M, Rodiño-Janeiro BK, Casado-Bedmar M, Lobo B, Vicario M, Santos J, et al. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. Neurogastroenterol Motil. 2016;28(4):463-486.

Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632.

Malagelada JR. The Brain-Gut Team. Dig Dis. 2020;38(4):293-298.

Kalantar JS, Locke 3rd GR, Zinsmeister AR, Beighley CM, Talley NJ. Familial aggregation of irritable bowel syndrome: a prospective study. Gut. 2003;52(12):1703-7.

Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804.

Mahurkar-Joshi S, Chang L. Epigenetic Mechanisms in Irritable Bowel Syndrome. Front Psychiatry. 2020;14;11:805

Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019;156(1):46-58.

Klem F, Wadhwa A, Prokop LJ Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042-54.

Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin N Am. 2021;50(2):445-461.

Saha S, Sehgal K, Singh S, Grover M, Pardi D, Khanna S Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection: A Systematic-review and Metaanalysis. J Clin Gastroenterol. 2022;56(2):e84-e93.

Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-811.

Sadeghi A, Biglari M, Nasseri Moghaddam S. Postinfectious irritable bowel syndrome: a narrative review. Middle East J Dig Dis. 2019;11(2):69-75.

Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010;16(1):30-34.

Morales W, Triantafyllou K, Parodi G, Wetsman S, Park SC, Rezaie A, et al. Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(10):e13875.

Morales W, Rezaie A, Barlow G, Pimentel M. SecondGeneration Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig Dis Sci. 2019;64(11):3115-3121.

Suliman Y, Kafaja S, Oh SJ, Alemam M, Bagnato G, Abignano G, Singh RR, et al. Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. Clin Rheumatol. 2021;40(6):2277-2284.

Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105(4):848-58.

Black CJ, Craig O, Gracie DJ, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110-6.

Black CJ, Ford AC. Rational investigations in irritable bowel syndrome. Front Gastroenterology. 2020;11(2):140-7.

Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. Ford AC British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240.

Asghar Z, Thoufeeq M, Kurien M, Ball AJ, Rej A, David Tai, et al. Diagnostic Yield of Colonoscopy in Patients With Symptoms Compatible With Rome IV Functional Bowel Disorders. Clin Gastroenterol Hepatol. Clin Gastroenterol Hepatol. 2022;20(2):334-341.

Black CJ. Review article: diagnosis and investigation of irritable bowel syndrome. Aliment Pharmacol Ther. 2021;45(Suppl.1):S33-S43.

Tack DM, Ray L, Griffin PM Cieslak PR, Dunn J, Rissman T, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food - foodborne diseases active surveillance network, 10 U.S. sites, 2016-2019. MMWR Morb Mortal Wkly Rep. 2020;69(17):509-14.

Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18(2):200-4.

Hill, AB. The environment and disease: association or causation? Proc R Soc Med, 1965;58(5):295-300.

Takakura W, Kudaravall P, Chatterjee C, Pimentel M, Riddle MS. Campylobacter infection and the link with Irritable Bowel Syndrome: on the pathway towards a causal Association. Pathog Dis. 2022;80(1):1-11.

Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M,et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J. 2017;5(6):773-788.

Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122(2):107-12

Kurlander JE, Chey WD, Morris CB, Hu YJB, Padival RK, Bangdiwala SI, et al. Development and validation of the Patient-Physician Relationship Scale among patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(10):1-8.

Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patientassessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008;103(10):2536-2543.

Lacy BE, Cangemi D, Vazquez-Roque M Management of Chronic Abdominal Distension and Bloating. Clin Gastroenterol Hepatol. 2021;19(2):219-231

Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32(2):144-58.

Lembo A, Rao SSC, Heimanson Z, Pimentel M. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Clin Transl Gastroenterol. 2020;11(3):e00144.

Brenner DM, Lacy BE. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. Am J Gastroenterol. 2021;116(8):1587-1600.

Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013;28(3):295-30.

Evangelista S, Traini C, Vannucchi MG. Otilonium Bromide: A Drug with a Complex Mechanism of Action. Curr Pharm Des. 2018;24(16):1772-79.

Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Therap Adv Gastroenterol. 2017;10(3):311-322.

Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(4):432-42.

Masuy I, Pannemans J, Tack J. Irritable bowel syndrome: diagnosis and management. Min Gastroenterol Dietol. 2020;66(2):136-50.

Boyer JC, Magous R, Christen MO, Balmes JL, Bali JP. Contraction of human circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. Cell Calcium. 2001;29(6):429-38.

Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, LópezColombo A, Mateos-Pérez GJ, Remes-Troche JM, et al. Efficacy of the Combination of Pinaverium Bromide 100mg Plus Simethicone 300mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial. J Clin Gastroenterol. 2020;54(4):30-39.

Zheng L, Lai Y, Lu W, Li B, Fan H, Yan Z, et al. Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial. Clin Gastroenterol Hepatol. 2015;13(7):1285-1292.

Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19(1):21.

Cash BD, Epstein MS, Shah SM.A. Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci. 2016;61(2):560-71.

Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, et al. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Adv Ther. 2018;35(11):1965-1978.

Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117-131.

Nee J, Lembo A. Review Article: Current and future treatment pproaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).Aliment Pharmacol Ther. 2021;54(Suppl 1): S63-S74.

Lembo A, Rao SSC, Heimanson Z, Pimentel M Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.Clin Transl Gastroenterol. 2020;11(3):e00144.

Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, et al.Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020;158(1):123-136.

Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum Al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(11- 12):1253-1269.

Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61.

Tornblom H, Drossman DA. Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Curr Gastroenterol Rep. 2018;20(12):58-56.

Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21-39.

Munjal A, Dedania B, Cash BD. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020;21(1):63-71.

Otero W, Otero L. Rifaximina: un antibiótico con otros efectos biológicos. En Otero W, Otero L, ed. Enfermedades digestivas tratables con antibióticos intraluminales México: McGrawHill; 2016. p.137-146.

Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557-63.

Blandizzia C, Viscomib GC, Marzoc A, Scarpignato C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison ofbranded and generic formulations in healthy volunteers. Pharmacological Research. 2014;85:39-44.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.

Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat Treatment with Rifaximin Is Safe and Effective in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016;151(6):1113-1121.

Ford AC, Harris LA, Lacy BE, Quingley EM, Moayyedi P. Systematic review with metaanalysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-60.

Chey WD, Shah ED, DuPont HL. Mechanism of action and therapeutic Benefit of rifaximin in patients with irritable bowel syndrome: a narrative review. Ther Adv Gastroenterol. 2020;13:175628481989753.

Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125(4):381-93.

Lacy BE. Review article: an analysis of safety profiles of the treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(8):817- 830.

Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125:381-93.

Shah E, Pimentel M. Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. Aliment Pharmacol Ther. 2014;39:973-983.

Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016;374(3):242-53.

Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2020;37(1):83-96.

Drug Safety and Availability [Internet]. U.S.Food and Drug administration. 2022 [consultado 1 de mayo 2021]. Disponible en: https://www.fda.gov/Drugs/DrugSafety/ Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31(5):463-468.

Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019;2(1):6-29.

Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1-18.

Wedlake L, A’Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7): 707-717.

Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, et al. Efficacy and safety of 5-hydroxy- tryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12(3):e0172846.

Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617-25.

Munjal A, Dedania B, Cash B. Update on Pharmacotherapy for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2019;21(6):25.

Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006;101(5):1069-79.

Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010;4(1):13-29.

Nee J, Zakari M, Lembo AJ. Novel Therapies in IBSD Treatment. Curr Treat Options Gastroenterol. 2015;13(4):432-40.

Chen L, Ilham SJ, Feng B. Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article. Anesth Pain Med. 2017;7(2): e42747.

Staller K, Cash BD. Myths and Misconceptions About Constipation: A New View for the 2020s. Am J Gastroenterol. 2020;115(11):1741-1745.

Black CJ, Burr NE, Ford AC. Relative Efficacy of Tegaserod in a Systematic Review and Network Metaanalysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. Clin Gastroenterol Hepatol. 2020;18(5):1238-1239.

Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol. 2014;109(9):1367-74.

Eswaran S, Muir J, Chey WD . Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:718 - 27.

Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154.

Drossman D.A, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome— Results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29;329-341.

Raschi E, De Ponti F. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2014;10(2):293-305

Love BL, Johnson A, Smith LS. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014;71(13):1081-91.

Layer P, Stanghellini V. Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39(4):371-84

Shailubhai K, Comiskey S, Foss JA, Feng R, Barrow L, Comer GM, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580-6.

Miner PB Jr, DeLuca R, LaPortilla M, et al. Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol. 2014;109: S541.

Markham A. Tenapanor: First Approval. Drugs. 2019;79(17):1897-1903.

Zielińska M,Wasilewski A, Fichna J. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Investig Drugs. 2015;24(8):1093-9.

Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idipathic constipation: Systematic review and meta-analysis. Gut. 2011;60:209-18.

Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193-217.

Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-1515.

Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(1):191-196.

Chassagne P, Ducrotte P, Garnier P, Mathiex-Fortunet H. Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax) Compared to Lactulose in Elderly Patients with Chronic Constipation. J Nutr Health Aging. 2017;21(4):429-439.

Rachel H, Griffith AF, Teague WJ, Hutson JM, Gibb S, Goldfeld S, et al. Polyethylene Glycol Dosing for Constipation in Children Younger Than 24 Months: A Systematic Review. J Pediatr Gastroenterol Nutr. 2020;71(2):171- 175.

Wald A. Constipation: Advances in Diagnosis and Treatment. JAMA 2016;;315(2):185-91.

Shah ED, Lacy BE, Chey WD, Chang L, Brenner DM. Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. Am J Gastroenterol. 2021;11688):1601-1611.

Jadallah KA, Kullab SM, Sanders DS. Consti- pationpredominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol. 2014;20(27):8898-909.

Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8(2):159-66.

Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al.Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74-82.152.

Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2016;66(5):980-982.

Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2021;160(1):145-157.

Ford AC, Harris LA, Lacy BE, Quigley EM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060.

et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26(2):66-77.

Yang M, Yu Y, Lei PG, Yuan J Comparative efficacy and safety of probiotics for the treatment of irritable bowel syndrome: a systematic review and network meta-analysis protocol. BMJ Open. 2019;9(12):e027376.

Eswaran S, Chey WD, Jackson K, Pillai S, Chey SW, Han-markey T. A low FODMAP diet improves quality of life, reduces activity impairment, and improves sleep quality in patients with irritable bowel syndrome and diarrhea: Results from a US randomized controlled trial. Clin Gastroenterol Hepatol. 2017;15(12):1890-9.

Dionne J, Ford AC, Yuan Y, Lacy BE, Saityo YA, Quigley EM, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten free diet and a low FODMAP diet in treating symptoms of IBS. Am J Gastroenterol. 2018;113(9):1290-300.

Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67- 75.

Hustoft TN, Hausken T, Ystad SO, Valeur J, Brokstad K, Hatlebakk JG, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(4).

Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified nice guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824-32.

Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-407.

Catassi G, Lionetti E, Gatti S, Catassi C. The Low FODMAP Diet: Many Question Marks for a Catchy Acronym. Nutrients. 2017;9(3):292.

Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527.

Hill P, Muir JG, Gibson PR. Controversies and Recent Developments of the Low-FODMAP Diet. Gastroenterol Hepatol (N Y). 2017;13(1):36-45.

Krogsgaard LR, Lyngesen M, Bytzer P. Systematic review: Quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. Aliment Pharmacol Ther. 2017;45(12):1506-13.

Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018;113(9):1290-1300.

Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21-39.

Johnsen PH, Hilpu ̈sch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota trans- plantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, ran- domised, placebo-controlled, parallel-group, single- centre trial. Lancet Gastroenterol Hepatol. 2017;3(1):17-24.

El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859-867.

Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, doubleblind placebo-controlled study. Gut. 2018;67(12):2107- 2115.

Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, et al. Randomised trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321-1331. 216. El-Salhy M, Hausken T, Hatlebakk JG. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients. 2019;11(6):1415 -1424.

Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-486.

Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B. & Mayer, E. A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-660.

Singh, P. Staller K, Dai E, Newman J, Yoon S, Castel S, et al. Patients with irritable bowel syndrome- diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J. Gastroenterol. 2015;21(26):8103-8109.

Buono, J, Carson R, Flores N. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.

Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, Morgan A, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20(7):455-62.

Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, et al.

International survey of patients with IBS: Symptom features and their severity, health status, treatments, and risk Taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50.

Descargas

Publicado

2022-11-17

Cómo citar

[1]
Otero R., W., Otero P., L. y Marulanda F., H. 2022. Síndrome de intestino irritable (SII): Nuevos conceptos en 2023 . Medicina. 44, 3 (nov. 2022), 347–371. DOI:https://doi.org/10.56050/01205498.2182.

Número

Sección

Artículos de Revisión